National registry for patients with moderate-to-severe atopic eczema

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The TREAT NL registry collects data on children and adults with moderate-to-severe atopic eczema who are receiving photo- or systemic immunomodulating therapies. This observational study aims to gather real-life data on the effectiveness, safety, and cost-effectiveness of these treatments, many of which are used off-label. By establishing a comprehensive registry, the study seeks to improve the quality of care for patients suffering from this chronic skin condition. The insights gained will help inform clinical practice and guide future treatment decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient has a diagnosis of atopic eczema, based on the U.K. working party's diagnostic criteria;
* Starts with any type of phototherapy (e.g. UVB) or systemic immunomodulating therapy (e.g. cyclosporin, systemic glucocorticosteroids, azathioprine, methotrexate, mycophenolic acid, dupilumab);
* Has voluntarily signed and dated an informed consent prior to any study related procedure or has a legal representative to do so and is willing to comply with the requirements of this study protocol.

Exclusion Criteria:

* Patient uses only (systemic) antibiotics or antihistamines;
* Patient starts with systemic immunomodulating therapy for another indication than atopic eczema;
* Insufficient understanding of the study by the patient or parent/legal representative.

Where it's running

• Department of Dermatology, Amsterdam University Medical Centres, University of Amsterdam, Research Institute Amsterdam Public Health and Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands
  Amsterdam, North Holland, Netherlands Recruiting

Study contacts

• Principal investigator: Phyllis I. Spuls, prof.dr. — Department of Dermatology, Amsterdam University Medical Centres, University of Amsterdam, Research Institute Amsterdam Public Health and Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands
• Study coordinator: Angela L. Bosma
• Email: a.l.bosma@amsterdamumc.nl
• Phone: +31205662757

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A Phase 3 test of Rezpegaldesleukin (NKTR-358) for moderate-to-severe atopic dermatitis in patients 12 years and older

  This Phase 3 study tests whether Rezpegaldesleukin helps people aged 12 and up with moderate-to-severe atopic dermatitis compared to placebo.

  Recruiting at 13 sites Phase 3 Nektar Therapeutics · Birmingham, Alabama and 12 other locations · NCT07711418

• Rezpegaldesleukin for moderate-to-severe atopic dermatitis in people 12 and older

  This study tests whether Rezpegaldesleukin helps people aged 12 and up with moderate-to-severe atopic dermatitis compared with a placebo.

  Recruiting at 20 sites Phase 3 Nektar Therapeutics · Phoenix, Arizona and 19 other locations · NCT07690371

• Nemolizumab for infants with moderate-to-severe atopic dermatitis

  This study tests whether nemolizumab can be safely given to infants aged 6 to under 24 months to help manage moderate-to-severe eczema when topical treatments alone aren’t enough.

  Recruiting Phase 2 Galderma R&D · San Antonio, Texas · NCT07660835

• SYX-5219 in healthy adults and adults with moderate-to-severe atopic dermatitis

  This trial will test oral SYX-5219 in healthy adults and in adults with moderate-to-severe atopic dermatitis to see if it is safe, well tolerated, and how the drug is processed in the body.

  Recruiting at 12 sites Phase 1 Sitryx Therapeutics Ltd · Arkansas City, Arkansas and 13 other locations · NCT07558668

• Oral LW402 for moderate-to-severe atopic dermatitis

  This phase 3 study tests whether oral LW402 tablets can help adults with moderate-to-severe atopic dermatitis compared with a placebo.

  Recruiting Phase 3 Shanghai Longwood Biopharmaceuticals Co., Ltd. · Beijing · NCT07370909

• SHR-1905 treatment for moderate-to-severe atopic dermatitis

  This trial will test whether SHR-1905 injections help adults aged 18–75 who have moderate-to-severe atopic dermatitis.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangdong · NCT07211542

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.